Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Epistemonikos ID: e7111afb2cc17c768f0f2b1db6bf5516b9f245a7
First added on: Apr 17, 2025